Skip to content
Enablex, Emselex(darifenacin hydrobromide)
Emselex, Enablex (darifenacin hydrobromide) is a small molecule pharmaceutical. Darifenacin hydrobromide was first approved as Emselex on 2004-10-22. It is used to treat overactive urinary bladder and urge urinary incontinence in the USA. It has been approved in Europe to treat overactive urinary bladder and urge urinary incontinence. It is known to target muscarinic acetylcholine receptor M3 and muscarinic acetylcholine receptor M1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Darifenacin hydrobromide
Tradename
Company
Number
Date
Products
ENABLEXAbbVieN-021513 DISCN2004-12-22
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
darifenacinANDA2022-12-01
darifenacinANDA2023-01-25
enablexNew Drug Application2010-01-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
overactive urinary bladderEFO_1000781D053201N32.81
urge urinary incontinenceEFO_0006865D053202N39.41
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04B: Urologicals
— G04BD: Drugs for urinary frequency and incontinence
— G04BD10: Darifenacin
HCPCS
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Overactive urinary bladderD053201EFO_1000781N32.81—132612
Healthy volunteers/patients—21—1—4
NocturiaD053158R35.1———1—1
Urinary incontinenceD014549HP_0000020R32———1—1
Spinal cord injuriesD013119EFO_1001919———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G35—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Therapeutic equivalencyD0138102————2
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G20————11
Renal colicD056844EFO_1001412N23————11
Postoperative painD010149G89.18————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDARIFENACIN HYDROBROMIDE
INNdarifenacin
Description
Darifenacin is 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence. It has a role as a muscarinic antagonist and an antispasmodic drug. It is a member of 1-benzofurans, a member of pyrrolidines and a monocarboxylic acid amide.
Classification
Small molecule
Drug classmuscarinic receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Br.NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1
Identifiers
PDB—
CAS-ID133099-04-4
RxCUI136198
ChEMBL IDCHEMBL1200935
ChEBI ID31455
PubChem CID444031
DrugBankDB00496
UNII IDAPG9819VLM (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CHRM3
CHRM3
CHRM1
CHRM1
Organism
Homo sapiens
Gene name
CHRM3
Gene synonyms
NCBI Gene ID
1131
Protein name
muscarinic acetylcholine receptor M3
Protein synonyms
acetylcholine receptor, muscarinic 3, m3 muscarinic receptor
Uniprot ID
Q9HB60
Mouse ortholog
Chrm3 (12671)
muscarinic acetylcholine receptor M3 (Q9ERZ3)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 799 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
535 adverse events reported
View more details